ADMA Biologics, Inc. (ADMA) Q3 2018 Earnings Results

ADMA Biologics Misses on EPS, Stock Down 0.35%

ADMA Biologics reported a loss per share of $0.33, which did not meet any consensus expectations. The stock reacted negatively, declining by 0.35%. The lack of revenue details and future guidance may have contributed to investor caution.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.33	N/A	N/A
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management expressed concerns about ongoing market challenges. They emphasized a commitment to operational improvements but did not offer specific future guidance.

Management did not provide specific guidance for future quarters.

The company is focused on improving operational efficiencies.

Challenges in the market continue to impact performance.

ADMA Biologics Misses on EPS, Stock Down 0.35%

Key numbers

Management commentary

ADMA Biologics, Inc.

More earnings this week

ADMA Biologics Misses on EPS, Stock Down 0.35%

Key numbers

Management commentary